Vyne Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

YARROW BIOSCIENCE

08/11/2024 16:31

* Vyne Therapeutics Inc  VYNE.OQ   VYNE.O  is expected
to show a
rise in quarterly revenue when it reports  results  for the
period ending December 31 2024
    * The Bridgewater New Jersey-based  company is expected to
report
a 163.2% increase in revenue to $200 thousand from $76 thousand
a year ago, according to the estimate from one analyst, based on
LSEG data.
    * ​LSEG's mean analyst estimate for Vyne Therapeutics Inc is
for a
loss of 25 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 14.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Vyne
Therapeutics
Inc is 5.75​, above​ its last closing price of $3.16. ​​​

This summary was machine generated November 8 at 16:31 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)